Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
Mirum Pharmaceuticals (MIRM) Stock Price & Analysis
589 Followers
MIRM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$23.14 - $35.56
Previous Close$24.76
Volume385.15K
Average Volume (3M)481.66K
Market Cap
$1.17B
Enterprise Value$1.19B
Total Cash (Recent Filing)$286.33M
Total Debt (Recent Filing)$308.14M
Price to Earnings (P/E)-6.6
Beta0.52
Next Earnings
Aug 01, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.77
Shares Outstanding47,133,021
10 Day Avg. Volume426,198
30 Day Avg. Volume481,661
Standard Deviation0.36
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-274.27
Price to Sales (P/S)6.26
Price to Cash Flow (P/CF)-17.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.65
Enterprise Value/Gross Profit6.38
Enterprise Value/Ebitda-9.33
Forecast
1Y Price Target
$44.63Price Target Upside80.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Mirum Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Development And ApprovalVolixibat's interim analyses are on target, potentially confirming its dose selection and continuing the study as planned, which could highlight the drug's effectiveness and impact its market positioning.
Financial PerformanceWith a robust cash position and consistent Livmarli sales, Mirum Pharmaceuticals reiterates its confidence in achieving the 2024 revenue guidance, signaling financial stability and growth potential.
Product Launch And Market OpportunityThe positive reception of Livmarli's launch for PFIC, along with a broad approval label, sets the stage for strong market penetration and revenue growth, enhancing Mirum Pharmaceuticals' commercial prospects.
Bears Say
Competitive Market ChallengesConcerns from experts about volixibat's position in the PBC treatment market due to competitive intensity highlight forecasted challenges.
Cybersecurity IncidentLivmarli revenue was below expectations, partly due to a cybersecurity incident affecting insurance processing.
Increased Operating ExpensesOperating expenses for the fourth quarter were higher than expected, suggesting that consensus 2024 operating expenses may be underestimated.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $23.14 and its highest was $35.56 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Aug 01, 2024 which is in 79 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on May 08, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.12.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -$0.44.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 47,133,022 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went up 3.155%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Among the largest hedge funds holding Mirum Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds Mirum Pharmaceuticals Inc’s shares valued at 16M.
---
Mirum Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.63 (80.10% Upside)
$44.63 (80.10% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 209.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $183.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.49%
12-Months-Change
Fundamentals
Return on Equity
-83.06%
Trailing 12-Months
Asset Growth
95.47%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
---
MIRM Earnings Call
Q1 2024
0:00 / 0:00
---
MIRM Stock 12 Month Forecast
Average Price Target
$44.63
▲(80.10% Upside)
Technical Analysis
MacroGenics
―
Corvus Pharmaceuticals
―
Arvinas Holding Company
―
Corbus Pharmaceuticals
―
Best Analysts Covering MIRM
1 Year
1 Year Success Rate
14/22 ratings generated profit
1 Year Average Return
+6.82%
reiterated a buy rating 7 months ago
Copying Steven Seedhouse's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +6.82% per trade.
---